Israel - Ibrani - Ministry of Health

medison pharma ltd - ivabradine as hydrochloride - טבליות מצופות פילם - ivabradine as hydrochloride 7.5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.

Israel - Ibrani - Ministry of Health

medison pharma ltd - ivabradine as hydrochloride - טבליות מצופות פילם - ivabradine as hydrochloride 5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.

Israel - Ibrani - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Israel - Ibrani - Ministry of Health

abbvie biopharmaceuticals ltd, israel - brimonidine tartrate; timolol as maleate - תמיסה לעין - timolol as maleate 0.5 %w/v; brimonidine tartrate 0.2 %w/v - brimonidine - brimonidine - combigan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Israel - Ibrani - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Israel - Ibrani - Ministry of Health

novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 10 mg / 1.5 ml - somatropin

Israel - Ibrani - Ministry of Health

novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 15 mg / 1.5 ml - somatropin

Israel - Ibrani - Ministry of Health

masrouji co, ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 5 mg / 1.5 ml - somatropin

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an